Skip to main content
. 2023 Apr 20;150(8):dev201112. doi: 10.1242/dev.201112

Fig. 3.

Fig. 3.

LATS inhibitor treatment in cow embryos. (A) Schematics of LATS inhibitor treatments in cow embryos. (B) Immunofluorescence analysis of YAP1, SOX2, GATA3 and DAPI nuclear staining in control and LATS inhibitor-treated, morula-stage cow embryos. (C) Quantification of YAP1, SOX2, GATA3 normalised fluorescence intensity in outer and inner cells in control and LATS inhibitor-treated, morula-stage cow embryos (n=93 cells from 4 control embryos and 201 cells from 7 treated embryos). (D) Immunofluorescence analysis of YAP1, SOX2, GATA3 and DAPI nuclear staining in control and LATS inhibitor-treated, expanded blastocyst-stage cow embryos. (E) Quantification of YAP1, SOX2, GATA3 normalised fluorescence intensity in TE and ICM cells in control and LATS inhibitor-treated, expanded blastocyst-stage cow embryos (n=1347 cells from 10 control embryos and 1223 cells from 9 treated embryos). Data are presented as mean±s.d. Two-tailed Mann–Whitney U-test: *P<0.05, **P<0.01, ****P<0.0001. ns, not significant. Scale bars: 30 µm.